Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10301 - 10325 of 12439 in total
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
Investigational
Matched Description: … the treatment of sickle cell disease. ... Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for …
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
Investigational
Matched Description: … of the hTERT subunit ... UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments …
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 ... SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. ... convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. ... Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide …
Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).
Investigational
Matched Description: … Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). ... Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
Investigational
Matched Description: … Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml ... Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial …
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … of fluid in the eye, is believed to be one of the principal causes of glaucoma. ... The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount ... PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Matched Description: … MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients ... Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 ... Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. ... can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of
Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.
Investigational
Matched Description: … Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue …
Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).
Investigational
Matched Description: … at Risk of Developing NVG). ... Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients …
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not ... under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of
Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
Investigational
Matched Description: … on Vascular Function - the Role of Endothelin). ... Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation …
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these...
Investigational
Matched Description: … Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was ... developed using domains of viral structural proteins and a polyprotein protease. ... Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, …
GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).
Investigational
Matched Description: … Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients ... With Painful Osteoarthritis of the Knee). ... GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the …
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum ... Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. ... As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled …
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid ... )-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … action of fucoxanthin is not fully elucidated. ... an animal model of duodenal, skin, colon and liver cancer. ... of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). …
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Investigational
Matched Description: … DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of
Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis).
Investigational
Matched Description: … the Treatment of Idiopathic Pulmonary Fibrosis). ... Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in …
Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)).
Investigational
Matched Description: … of Postoperative Crohn's Disease (CD)). ... Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence …
Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
Investigational
Matched Description: … Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 …
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. ... This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder …
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase ... VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions …
Displaying drugs 10301 - 10325 of 12439 in total